Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes

Nauck, Michael, Frid, Anders, Hermansen, Kjeld, Shah, Nalini S., Tankova, Tsvetalina, Mitha, Ismail H., Zdravkovic, Milan, Düring, Maria +2 more·2009·Diabetes Care
DOI 10.2337/dc08-1355

Cited by (999)

Items 701–800 of 999

  1. Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta‐analysis of the liraglutide phase III clinical trial programme
    Eduard Montanya, Vivian Andrew Fonseca, Stephen Colagiuri, Lawrence Blonde, Morten Donsmark, Michael Albrecht Nauck · 2015 · Diabetes Obesity and Metabolism
  2. Impact of diabetes duration on achieved reductions in glycated haemoglobin, fasting plasma glucose and body weight with liraglutide treatment for up to 28 weeks: a meta‐analysis of seven phase III trials
    Jochen Seufert, Timothy Silleck Bailey, S. Barkholt Christensen, Michael Albrecht Nauck · 2015 · Diabetes Obesity and Metabolism
  3. Efficacy and Clinical Characteristics of Liraglutide in Japanese Patients With Type 2 Diabetes
    Daisuke Ito, Takujiro Iuchi, Susumu Kurihara, Ikuo Inoue, Shigehiro Katayama, Kouichi Inukai · 2015 · Journal of Clinical Medicine Research
  4. Incretin-based Therapy in Chronic Kidney Disease
    Nicole R. Pinelli, Carol L. Moore, Sarah Tomasello · 2010 · Advances in Chronic Kidney Disease
  5. Anti-Obesity Pharmacotherapy and the Potential for Preventing Progression from Prediabetes to Type 2 Diabetes
    Alan J. Garber · 2015 · Endocrine Practice
  6. Add-on therapy with anagliptin in Japanese patients with type-2 diabetes mellitus treated with metformin and miglitol can maintain higher concentrations of biologically active GLP-1/total GIP and a lower concentration of leptin
    Takeshi Osonoi, Miyoko Saito, Natsuyo Hariya, Moritaka Goto, Kazuki Mochizuki · 2016 · Peptides
  7. Liraglutide for type 2 diabetes mellitus
    Ram Kela, Kamlesh K. Khunti, Melanie Jane Davies · 2011 · Expert Opinion on Biological Therapy
  8. Type 2 Diabetes in Adults
    2011 · Wiley eBooks
  9. Pharmacologic treatment of obesity in adults: Standards of care in overweight and obesity
    Kimberly A. Caroline M. Vanita R. Louis J. Kirthikaa Alliso Gudzune Apovian Aroda Aronne Balapattabi Bennett C · 2025 · BMJ Open Diabetes Research & Care
  10. The Role of the Pharmacist in Managing Type 2 Diabetes with Glucagon-Like Peptide-1 Receptor Agonists as Add-On Therapy
    Jerry D. Meece · 2017 · Advances in Therapy
  11. Semaglutide and obesity: beyond the nutritional and lifestyle intervention?
    Livia Basile, Rossella Cannarella, Stefano Iuliano, Aldo Eugenio Calogero, Rosita Angela Condorelli, Emanuela Alessandra Greco, Antônio Aversa, Sandro La Vignera · 2024 · Minerva Endocrinology
  12. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
    Alan J. Garber · 2011 · PubMed
  13. Glucagon‐like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective
    Miles Fisher · 2014 · Diabetes Obesity and Metabolism
  14. Novel role for the incretins in blood pressure regulation
    Preethi Yerram, Adam T. Whaley‐Connell · 2012 · Current Opinion in Nephrology & Hypertension
  15. Current cardiovascular outcomes trials in type 2 diabetes: Perspectives and insight
    Reilly W. Coch, J.B. Green · 2016 · Nutrition Metabolism and Cardiovascular Diseases
  16. Testing of non-inferiority and superiority for three-arm clinical studies with multiple experimental treatments
    Junjiang Zhong, Miin-Jye Wen, Koon Shing Kwong, Siu Hung Cheung · 2016 · Statistical Methods in Medical Research
  17. Adaptive Designs for Non-inferiority Trials with Multiple Experimental Treatments
    Wenfu Xu, Feifang Hu, Siu Hung Cheung · 2017 · Statistical Methods in Medical Research
  18. Basal and stimulated calcitonin levels in patients with type 2 diabetes did not change during 1 year of Liraglutide treatment
    Maria Elena Lunati, Valeria Grancini, Carla Maria Colombo, Eva Palmieri, Veronica Resi, Michela Perrino, Emanuela Orsi, Laura Fugazzola · 2015 · Metabolism
  19. Choosing Appropriate Glucagon-like Peptide 1 Receptor Agonists: A Patient-Centered Approach
    Sanjay Kalra · 2014 · Diabetes Therapy
  20. Current treatments and strategies for type 2 diabetes: Can we do better with GLP-1 receptor agonists?
    Gregory Mark Peterson · 2012 · Annals of Medicine
  21. Bacterial organisms and antimicrobial resistance patterns.
    George Kuttiparichel Varghese, Chiranjay Mukhopadhya, Indira Bairy, K.E. Vandana, Muralidhar D Varma · 2010 · PubMed
  22. Benefits and challenges of a QSP approach through case study: Evaluation of a hypothetical GLP-1/GIP dual agonist therapy
    Theodore R. Rieger, Cynthia J. Musante · 2016 · European Journal of Pharmaceutical Sciences
  23. Effectiveness and Safety of Newer Antidiabetic Medications for Ramadan Fasting Diabetic Patients
    Ehab Mudher Mikhael · 2016 · Journal of Diabetes Research
  24. Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus: A Position Statement of the Korean Diabetes Association
    Hyun Jin Kim, Seok O Park, Seung‐Hyun Ko, Sang Youl Rhee, Kyu Yeon Hur, Nan Hee Kim, Min Kyong Moon, Byung‐Wan Lee, Jin Hwa Kim, Kyung Mook Choi · 2017 · Diabetes & Metabolism Journal
  25. Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: Individual effects of treatment
    Emilie H. Zobel, Bernt Johan von Scholten, Bryan Goldman, Frederik Persson, Tine W. Hansen, Peter R Rossing · 2019 · Diabetes Obesity and Metabolism
  26. Glycaemic control with liraglutide: the phase 3 trial programme
    Philip Raskin, Pablo F. Mora · 2010 · International Journal of Clinical Practice
  27. Is a Switch From Insulin Therapy to Liraglutide Possible in Japanese Type 2 Diabetes Mellitus Patients?
    Takehiro Kawata · 2014 · Journal of Clinical Medicine Research
  28. CCR2 knockout exacerbates cerulein-induced chronic pancreatitis with hyperglycemia via decreased GLP-1 receptor expression and insulin secretion
    Yuji Nakamura, Takanori Kanai∥, Keita Saeki, Miho Takabe, Junichiro Irie, Jun Miyoshi, Yohei Mikami, Toshiaki Teratani, Takahiro Suzuki, Naoteru Miyata et al. · 2013 · American Journal of Physiology-Gastrointestinal and Liver Physiology
  29. The physiologic role of incretin hormones: clinical applications.
    William T. Cefalu · 2010 · PubMed
  30. The effect and mechanism of liraglutide on the biological functions of BMSCs in diabetic patients
    Yao Wang, Yujie Sun, Bo Yang, Jun Li, Chao Liang · 2024 · Oral Diseases
  31. Use of glucagon‐like peptide‐1 receptor agonists and incretin mimetics for type 2 diabetes and obesity: A narrative review
    Jason F. Zupec, Rebecca Munger, Alice Scaletta, Diane H. Quinn · 2025 · Nutrition in Clinical Practice
  32. Efficacy of Liraglutide in clinical practice: Single centre experience
    Muhammad Owais Rashid, Sumerah Jabeen, Adeel Akbar Khoja, Najmul Islam · 2020 · Pakistan Journal of Medical Sciences
  33. Key considerations in pharmacotherapy for type 2 diabetes mellitus: a multiple target organ approach
    Susan A. Cornell · 2011 · Journal of Clinical Pharmacy and Therapeutics
  34. Partnering with Patients to Improve Therapeutic Outcomes: Incretin-Based Therapy for Type 2 Diabetes
    Daniel A. Nadeau · 2010 · Postgraduate Medicine
  35. Clinical Effectiveness of Liraglutide vs Sitagliptin on Glycemic Control and Body Weight in Patients with Type 2 Diabetes: A Retrospective Assessment in Sweden
    Marcus Lind, Per-Olov Matsson, Ragnar Linder, Irene Svenningsson, Leif Jørgensen, Uffe Jon Ploug, Helge Gydesen, Mozhgan Dorkhan, Sara Larsen, Gunnar S Johansson · 2016 · Diabetes Therapy
  36. Liraglutide – Indian Experience
    Anirban Majumder, Soumyabrata Roy Chaudhuri, Debmalya Sanyal, Kingshuk Bhattacharjee · 2018 · Indian Journal of Endocrinology and Metabolism
  37. Incretin therapy for type 2 diabetes: GLP-1 receptor agonists and DPP-4 inhibitors
    Bo Åhrén · 2013 · European Diabetes Nursing
  38. Liraglutide: a human GLP-1 analog for Type 2 diabetes
    Tina Vilsbøll · 2009 · Therapy
  39. Managing Special Populations Among Patients with Type 2 Diabetes Mellitus
    Jonathan G. Marquess · 2011 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  40. Current Management of Obesity in an Infertile Female-Recent Advances and Future Prospective Drugs
    Kulvinder Kochar Kaur, Gautam Allahbadia, Mandeep Singh · 2013 · Journal of Pharmacy and Nutrition Sciences
  41. Prevalence and Predictors of Metformin Prescribing in Adults with Type 2 Diabetes Mellitus: A National Cross‐Sectional Study
    Mate Michael Soric, John Michael Moorman, Jaclyn A. Boyle, Samuel D. Crish · 2016 · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy
  42. Long-term efficacy of liraglutide in Indian patients with Type 2 diabetes in a real-world setting
    Parjeet Kaur, Shama Mahendru, Ambrish Mithal · 2016 · Indian Journal of Endocrinology and Metabolism
  43. Multi-perspective patient representation learning for disease prediction on electronic health records
    Ziyue Yu, Jiayi Wang, Wuman Luo, Rita T. Tse, Giovanni Pau · 2024 · Knowledge and Information Systems
  44. GLP-1 receptor agonists efficacy in managing comorbidities associated with diabetes mellitus: a narrative review
    Mahshad Gholami, Narges Zargar Balajam, Seyedeh Samira Rakhsha, Sayed Mahmoud Sajjadi‐Jazi, Gita Shafiee, Ramin Heshmat · 2025 · Journal of Diabetes & Metabolic Disorders
  45. The Preventive Effects of GLP-1 Receptor Agonists and SGLT2 Inhibitors on Cancer Metastasis: A Network Meta-Analysis of 67 Randomized Controlled Trials
    Chih‐Wei Hsu, Bing‐Syuan Zeng, Chih‐Sung Liang, Bing‐Yan Zeng, Chao‐Ming Hung, Brendon Stubbs, Yen‐Wen Chen, Wei‐Te Lei, Jiann-Jy Chen, Po‐Huang Chen et al. · 2025 · International Journal of Molecular Sciences
  46. Divergent Risks of Hematologic Malignancies Associated with GLP-1 Receptor Agonists and SGLT2 Inhibitors: Preliminary Findings from a Pilot Network Meta-Analysis
    Pao‐Yen Lin, Bing‐Yan Zeng, Chih‐Wei Hsu, Mein‐Woei Suen, Chao‐Ming Hung, Brendon Stubbs, Yen-Wen Chen, Tien‐Yu Chen, Wei‐Te Lei, Jiann-Jy Chen et al. · 2025 · Biomolecules
  47. Novel therapies for the management of type 2 diabetes mellitus: Part 2. Addressing the incretin defect in the clinical setting in 2013 (新型2型糖尿病治疗药物：第2部分. 2013年临床上针对肠促胰岛素缺陷的治疗药物)
    George Grunberger · 2013 · Journal of Diabetes
  48. Treatment evaluation of liraglutide in type 2 diabetes
    Ram Kela, Melanie Jane Davies · 2012 · Expert Opinion on Biological Therapy
  49. A systematic review of the safety of incretin-based therapies in type 2 diabetes
    Marc Evans, Stephen Charles Bain, Jiten P Vora · 2016 · Expert Review of Endocrinology & Metabolism
  50. Effectiveness and cost-effectiveness of six GLP-1RAs for treatment of Chinese type 2 diabetes mellitus patients that inadequately controlled on metformin: a micro-simulation model
    Shuai Yuan, Yingyu Wu · 2023 · Frontiers in Public Health
  51. Cutting-Edge Approaches to Obesity Management: The Latest Pharmacological Options
    Sarah H. Schmitz, Katherine H. Saunders, Louis J. Aronne · 2025 · Endocrinology and Metabolism Clinics of North America
  52. Systematic Review and Network Meta-analysis to Compare Dapagliflozin with other Diabetes Medications in Combination with Metformin for Adults with Type 2 Diabetes
    Barnett Ah, Orme ME · 2014 · Internal Medicine Open Access
  53. GLP-1 Receptor Agonists for Type 2 Diabetes and Their Role in Primary Care: An Australian Perspective
    Roy R. Rasalam, John Barlow, Mark Kennedy, Pat Phillips, Alan F. Wright · 2019 · Diabetes Therapy
  54. Changing the approach to type 2 diabetes treatment: A comparison of glucagon‐like peptide‐1 receptor agonists and sulphonylureas across the continuum of care
    Marco Orsini Federici, Raffaella Gentilella, Antonella Corcos, Enrico Torre, Stefano Genovese · 2021 · Diabetes/Metabolism Research and Reviews
  55. Efficacy and safety of dulaglutide compared with glargine in patients with type 2 diabetes: A systematic review and meta‐analysis
    Jun Xu, Danzhen Yao, Jinying Xia · 2021 · Journal of Clinical Pharmacy and Therapeutics
  56. Efficacy and Safety of a Biosimilar Liraglutide (Melitide®) Versus the Reference Liraglutide (Victoza®) in People with Type 2 Diabetes Mellitus: A Randomized, Double-Blind, Noninferiority Clinical Trial
    Alireza Esteghamati, Mehran Zamanzadeh, Mojtaba Malek, Mohammad Khaledi, AREZOO MONAVVARI, Laily Najafi, Zahra Banazadeh, Ramin Malboosbaf, Rokhsareh Aghili, Sedigheh Mahdikhah et al. · 2023 · Diabetes Therapy
  57. Spline‐based procedures for dose‐finding studies with active control
    Hans‐Joachim Helms, Norbert Benda, Jörg Zinserling, Thomas Kneib, Tim Friede · 2014 · Statistics in Medicine
  58. Managing Type 2 Diabetes in the Primary Care Setting: Beyond Glucocentricity
    Louis Kuritzky · 2010 · The American Journal of the Medical Sciences
  59. Blood Pressure and Cardiovascular Effects of New and Emerging Antidiabetic Agents
    Pelbreton C. Balfour, Carlos J. Rodríguez, Keith C. Ferdinand · 2014 · Current Hypertension Reports
  60. Insulin treatment and longer diabetes duration both predict poorer glycaemic response to liraglutide treatment in type 2 diabetes: the Association of British Clinical Diabetologists Nationwide Liraglutide Audit
    Ken Y Thong, Barbara M. McGowan, Thein Htay, Andrew Pernet, Chris Kelly, Chinnadorai Rajeswaran, Jill Howell, Catriona Duncan, Berit Inkster, Linda Buchanan et al. · 2015 · The British Journal of Diabetes
  61. Effects on repetitive 24-hour ambulatory blood pressure in subjects with type II diabetes randomized to liraglutide or glimepiride treatment both in combination with metformin: a randomized open parallel-group study
    JOHAN H. JENDLE, Xin Lei Fang, Yang Cao, Leif Bojö, Bo Nilsson, Fredric Hedberg, Irene Santos‐Pardo, Thomas Nyström · 2018 · Journal of the American Society of Hypertension
  62. Impact of Active Antihyperglycemic Components as Herbal Therapy for Preventive Health Care Management of Diabetes
    Harsha Kashyap, Sarika Gupta, Renu Bist · 2019 · Current Molecular Medicine
  63. [Liraglutide (Victoza): human glucagon-like peptide-1 used in once daily injection for the treatment of type 2 diabetes].
    André Jacques Scheen, Luc F. Van Gaal · 2010 · PubMed
  64. Therapeutic Options that Provide Glycemic Control and Weight Loss for Patients with Type 2 Diabetes
    Thomas Blevins · 2010 · Postgraduate Medicine
  65. Effect of Cosmos caudatus (Ulam raja) supplementation in patients with type 2 diabetes: Study protocol for a randomized controlled trial
    Shi-Hui Cheng, Amin Ismail, Joseph Anthony, Ooi Chuan Ng, Azizah Abdul Hamid, Barakatun Nisak Mohd Yusof · 2016 · BMC Complementary and Alternative Medicine
  66. Chinese herbal medicine is associated with higher body weight reduction than liraglutide among the obese population: A real-world comparative cohort study
    Liao, Yu-Ning, Chen, Hsing-Yu, Yang, Ching-Wei, Lee, Pai-Wei, Hsu, Chiu-Yi, Huang, Yu-Tung, Yang, Tsung-Hsien · 2022 · Frontiers in Pharmacology
  67. The gynecologic tumor risk related to GLP-1 receptor agonists and SGLT2 inhibitors use: a network meta-analysis of 91 randomized controlled trials
    Ping‐Tao Tseng, Bing‐Yan Zeng, Chih-Wei Hsu, Cheuk‐Kwan Sun, Mein‐Woei Suen, André F. Carvalho, Brendon Stubbs, Yen‐Wen Chen, Tien‐Yu Chen, Wei‐Te Lei et al. · 2025 · Journal of Hematology & Oncology
  68. Evidence-Based Practice Use of Incretin-Based Therapy in the Natural History of Diabetes
    Stanley S. Schwartz · 2014 · Postgraduate Medicine
  69. Systematic review of the efficacy and safety of GLP-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus
    Lora Petrova, Kalina Andreevska, Iva Parvova, Valentina Boyanova Petkova · 2024 · Pharmacia
  70. Current Issues in Glp-1 Receptor Agonist Therapy for Type 2 Diabetes
    Zachary T. Bloomgarden, Lawrence Blonde, Alan J. Garber, Carol Wysham · 2012 · Endocrine Practice
  71. Incretin-Based Therapy for Type 2 Diabetes Mellitus
    Israel Hartman, Edward Rojas, Daloha Rodríguez-Molina · 2013 · American Journal of Therapeutics
  72. Implementing CER: What Will It Take?
    JOSEPH E. BISKUPIAK, Jeffrey D. Dunn, Anke‐Peggy Holtorf · 2012 · Journal of Managed Care Pharmacy
  73. A review of glycemic efficacy of liraglutide once daily in achieving glycated hemoglobin targets compared with exenatide twice daily, or sitagliptin once daily in the treatment of type 2 diabetes
    Khalid Z. Alshali, Abdullah M. Karawagh · 2016 · Saudi Medical Journal
  74. Quality of Life, Glycemic Control, Safety and Tolerability Associated with Liraglutide or Insulin Initiation in Patients with Type 2 Diabetes in Germany: Results from the Prospective, Non-interventional LIBERTY Study
    Rainer Lundershausen, Sabrina Müller, Mahmoud Hashim, Joachim Kienhöfer, Stefan Kipper, Thomas Wilke · 2018 · Experimental and Clinical Endocrinology & Diabetes
  75. Degree of obesity and gastrointestinal adverse reactions influence the weight loss effect of liraglutide in overweight or obese patients with type 2 diabetes
    Fang Zhou, Lu Jiang, Jiamei Guo, Yuting Fan, Qin Pan, Tianlian Li, Xiaoshi Sun, Ping Li · 2023 · Therapeutic Advances in Chronic Disease
  76. Advancements in the management of obesity: a review of current evidence and emerging therapies
    Mohammed Altigani Abdalla Ahmed, Emmanuel Ssemmondo, Charlotte Mark-Wagstaff, T. Sathyapalan · 2024 · Expert Review of Endocrinology & Metabolism
  77. Managing insulin resistance: role of liraglutide
    Sharma · 2010 · Clinical Pharmacology Advances and Applications
  78. Treating type 2 diabetes: incretin mimetics and enhancers
    Katherine E. Nori Janosz, Kerstyn C. Zalesin, Wendy M. Miller, Peter Andrew McCullough · 2009 · Therapeutic Advances in Cardiovascular Disease
  79. ABCD position statement on incretin mimetics and DPP‐4 inhibitors ‐2009
    C. M. B. Edwards, Peter H. Winocour · 2009 · Practical Diabetes
  80. β-cell preservation and regeneration for diabetes treatment: where are we now?
    Michael Karadimos, Archana Kapoor, Ilham El Khattabi, Arun Sharma · 2012 · Diabetes Management
  81. Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.
    Michael Psallas, C. Manes · 2012 · Europe PMC (PubMed Central)
  82. Liraglutide, GLP-1 receptor agonist, for chronic weight loss
    Katherine G. Moore, Kayce M. Shealy, Jennifer Nicole Clements · 2016 · Expert Review of Endocrinology & Metabolism
  83. Liraglutide effect and action in diabetes-In (LEAD-In): A prospective observational study assessing safety and effectiveness of liraglutide in patients with type 2 diabetes mellitus treated under routine clinical practice conditions in India
    Subhash Kumar Wangnoo, Surender Kumar, Arpandev Bhattacharyya, Sudhir Tripathi, Shahid Akhtar, Raman Shetty, Samit Ghosal · 2016 · Indian Journal of Endocrinology and Metabolism
  84. How to prevent medication errors: a multidimensional scaling study to investigate the distinguishability between self-injection platform device variants
    Andreas Schneider, Harald Kolrep, Christoph Jordi, Philipp Richard, Hanns-Peter Horn, Jakob Lange · 2019 · Expert Opinion on Drug Delivery
  85. Effects of liraglutide addition to multiple diabetes regimens on weight and risk of hypoglycemia for a cohort with type 2 diabetes followed in primary care clinics in Saudi Arabia
    Ayla M. Tourkmani, YasserA Albarkah, Abdulaziz M. Bin Rsheed, Turki J Al Harbi, Yasser A Ebeid, Reuof A. Bushnag · 2019 · Journal of Family Medicine and Primary Care
  86. It Is Time to Consider Glucagon-Like Peptide-1 Receptor Agonists for the Treatment of Type 2 Diabetes in Youth
    Megan O. Bensignor, Aaron S. Kelly · 2019 · Frontiers in Endocrinology
  87. Oral glucose‐stimulated serum C ‐peptide predicts successful switching from insulin therapy to liraglutide monotherapy in Japanese patients with type 2 diabetes and renal impairment
    Hisazumi Araki, Yuki Tanaka, S Yoshida, Yoshikata Morita, Shinji Kume, Keiji Isshiki, Shin‐ichi Araki, Takashi Uzu, Atsunori Kashiwagi, Hiroshi Maegawa · 2013 · Journal of Diabetes Investigation
  88. The impact of insulin resistance on woman's health and potential treatment options
    Konstantinos B. Lois, Georgios Valsamakis, George P. Mastorakos, Sudhesh Kumar · 2010 · Annals of the New York Academy of Sciences
  89. Drug Information Rounds
    1997 · Annals of Pharmacotherapy
  90. The role of glucagon-like peptide-1/GLP-1R and autophagy in diabetic cardiovascular disease
    Zi Guo · 2024 · Pharmacological Reports
  91. The Enteric Neuronal Circuitry: A Key Ignored Player in Nutrient Sensing Along the Gut–Brain Axis
    Ester Nikolla, Ava Grandberry, Destiné Jamerson, Charles Robb Flynn, Sinju Sundaresan · 2025 · The FASEB Journal
  92. Glucagon-like peptide-1 receptor agonists: Evolution, gastrointestinal adverse effects, and future directions
    Alaa Ismail, Mohab Sherif Amer, Ahmed Tawheed · 2025 · World Journal of Gastrointestinal Pharmacology and Therapeutics
  93. Reassessing cancer risk with GLP-1 receptor agonists: a comprehensive meta-analysis of gastrointestinal malignancies
    Adil Farooq Wali, Imran Rashid Rangraze, Shehla Shafi Khan, Uwais Mufti, Mohamed El‐Tanani, Manfredi Rizzo · 2026 · Frontiers in Pharmacology
  94. Glucagon-like Peptide-1 Receptor Agonists: Exciting Avenues Beyond Weight Loss
    Lalitha Vani Sundararaman, Divakara Gouda, Anil Kumar, Sumithra Sundararaman, Basavana Goudra · 2025 · Journal of Clinical Medicine
  95. Individualized Treatment of Type 2 Diabetes Mellitus Using Noninsulin Agents: Clinical Considerations for the Primary Care Physician
    N. Bohannon · 2012 · Postgraduate medicine
  96. Rising Drug Costs Drives the Growth of Pharmacy Benefit Managers Exclusion Lists: Are Exclusion Decisions Value‐Based?
    Joshua Cohen, Christelle El Khoury, Christopher‐Paul Milne, Sandra M. Peters · 2017 · Health Services Research
  97. Polymeric microparticle systems for modified release of glucagon-like-peptide-1 receptor agonists
    Luis Peña Icart, Fernando Gomes de Souza, Luís Maurício T. R. Lima · 2021 · Journal of Microencapsulation
  98. Research in brief: Effective pharmacotherapy for the management of obesity
    Tessa M. Cacciottolo, Kate Evans · 2021 · Clinical Medicine
  99. Antidiabetika
    Alfred G. Wirth · 2011 · Der Internist
  100. Clinical efficacy of GLP-1 agonists and their place in the diabetes treatment algorithm.
    Jeff Unger · 2011 · PubMed